# Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor

> **NCT05301972** · — · NO_LONGER_AVAILABLE · sponsor: **Bristol-Myers Squibb**

## Conditions studied

_None listed._

## Interventions

- **DRUG:** BET Inhibitor

## Key facts

- **NCT ID:** NCT05301972
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05301972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05301972, "Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05301972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*